About Arbutus Biopharma Corporation (NASDAQ:ABUS)
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:ABUS
- CUSIP: N/A
- Web: www.arbutusbio.com
- Debt-to-Equity Ratio: 0.08%
- Current Ratio: 11.03%
- Quick Ratio: 11.03%
Sales & Book Value:
- Annual Sales: $1.5 million
- Price / Sales: 211.03
- Cash Flow: $5.93 per share
- Price / Cash: 0.97
- Book Value: $3.04 per share
- Price / Book: 1.89
- Trailing EPS: ($4.97)
- Net Income: ($384,160,000.00)
- Return on Equity: -34.98%
- Return on Assets: -24.76%
- Employees: 122
- Outstanding Shares: 55,050,000
Frequently Asked Questions for Arbutus Biopharma Corporation (NASDAQ:ABUS)
What is Arbutus Biopharma Corporation's stock symbol?
Arbutus Biopharma Corporation trades on the NASDAQ under the ticker symbol "ABUS."
How were Arbutus Biopharma Corporation's earnings last quarter?
Arbutus Biopharma Corporation (NASDAQ:ABUS) released its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.11. The biopharmaceutical company had revenue of $4.10 million for the quarter, compared to analyst estimates of $3.37 million. View Arbutus Biopharma Corporation's Earnings History.
When will Arbutus Biopharma Corporation make its next earnings announcement?
Where is Arbutus Biopharma Corporation's stock going? Where will Arbutus Biopharma Corporation's stock price be in 2017?
6 equities research analysts have issued 12 month price targets for Arbutus Biopharma Corporation's stock. Their forecasts range from $5.00 to $32.00. On average, they anticipate Arbutus Biopharma Corporation's share price to reach $13.00 in the next year. View Analyst Ratings for Arbutus Biopharma Corporation.
What are Wall Street analysts saying about Arbutus Biopharma Corporation stock?
Here are some recent quotes from research analysts about Arbutus Biopharma Corporation stock:
- 1. According to Zacks Investment Research, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. " (11/7/2017)
- 2. Wedbush analysts commented, "We believe ABUS remains undervalued ahead of key clinical readouts in 2017 for its HBV pipeline candidates, a mid:17 readout of Alnylam's Ph 3 patisiran study in ATTR that could lead to a significant royalties to ABUS, and the potential for additional partnerships around its attractive LNP platform." (3/22/2017)
Who are some of Arbutus Biopharma Corporation's key competitors?
Some companies that are related to Arbutus Biopharma Corporation include AC Immune SA (ACIU), OptiNose (OPTN), TG Therapeutics (TGTX), Concert Pharmaceuticals (CNCE), Kala Pharmaceuticals (KALA), PDL BioPharma (PDLI), Celyad SA (CYAD), Mesoblast Limited (MESO), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), Voyager Therapeutics (VYGR), Novavax (NVAX), Cara Therapeutics (CARA), Celldex Therapeutics (CLDX), Agenus (AGEN), Protagonist Therapeutics (PTGX), NewLink Genetics Corporation (NLNK) and Horizon Discovery Group PLC (HZD).
Who are Arbutus Biopharma Corporation's key executives?
Arbutus Biopharma Corporation's management team includes the folowing people:
- Vivek Ramaswamy, Chairman of the Board (Age 30)
- Mark J. Murray Ph.D., President, Chief Executive Officer, Director (Age 67)
- Bruce G. Cousins, Chief Financial Officer, Executive Vice President (Age 55)
- Elizabeth Howard, Executive Vice President, General Counsel (Age 62)
- Peter Lutwyche Ph.D., Chief Technology Officer (Age 50)
- Michael Joseph Sofia, Chief Scientific Officer (Age 57)
- William Thomas Symonds III, Chief Development Officer, Director (Age 48)
- Michael J. Abrams Ph.D., Managing Director - Non-HBV Assets (Age 59)
- Patrick T. Higgins, Chief Business Officer (Age 58)
- Daniel D. Burgess, Director (Age 55)
Who owns Arbutus Biopharma Corporation stock?
Arbutus Biopharma Corporation's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include RTW Investments LP (9.57%), Ladenburg Thalmann Financial Services Inc. (3.21%), K2 Principal Fund L.P. (0.45%), Point72 Asset Management L.P. (0.41%) and OxFORD Asset Management LLP (0.23%). View Institutional Ownership Trends for Arbutus Biopharma Corporation.
Who sold Arbutus Biopharma Corporation stock? Who is selling Arbutus Biopharma Corporation stock?
Who bought Arbutus Biopharma Corporation stock? Who is buying Arbutus Biopharma Corporation stock?
How do I buy Arbutus Biopharma Corporation stock?
Shares of Arbutus Biopharma Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arbutus Biopharma Corporation's stock price today?
One share of Arbutus Biopharma Corporation stock can currently be purchased for approximately $5.75.
How big of a company is Arbutus Biopharma Corporation?
Arbutus Biopharma Corporation has a market capitalization of $316.55 million and generates $1.5 million in revenue each year. The biopharmaceutical company earns ($384,160,000.00) in net income (profit) each year or ($4.97) on an earnings per share basis. Arbutus Biopharma Corporation employs 122 workers across the globe.
How can I contact Arbutus Biopharma Corporation?
Arbutus Biopharma Corporation's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]
MarketBeat Community Rating for Arbutus Biopharma Corporation (NASDAQ ABUS)MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Arbutus Biopharma Corporation (NASDAQ:ABUS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 5 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.83)|
|Consensus Price Target: ||$13.00 (126.09% upside)|
Consensus Price Target History for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Analysts' Ratings History for Arbutus Biopharma Corporation (NASDAQ:ABUS)
(Data available from 11/19/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/7/2017||Leerink Swann||Reiterated Rating||Market Perform||$4.00 -> $5.00||N/A|
|10/4/2017||JMP Securities||Reiterated Rating||Outperform||$12.00 -> $13.00||High|
|9/13/2017||Chardan Capital||Reiterated Rating||Buy||High|
|6/2/2017||Ladenburg Thalmann Financial Services||Initiated Coverage||Buy||$32.00||Low|
|1/9/2017||Bloom Burton||Upgrade||Accumulate -> Buy||N/A|
|8/21/2016||William Blair||Reiterated Rating||Outperform||N/A|
|12/21/2015||Royal Bank Of Canada||Lower Price Target||$20.00 -> $12.00||N/A|
Earnings History and Estimates Chart for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Earnings History by Quarter for Arbutus Biopharma Corporation (NASDAQ ABUS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/20/2018|| || || || || || || || |
|5/4/2017||3/31/2017||($0.30)||($0.34)||$7.50 million||$0.20 million||View||Listen|
|11/5/2015||Q3 2015||($0.31)||($0.42)||$3.37 million||$4.10 million||View||N/A|
|8/5/2015||Q2||($0.25)||($0.20)||$3.77 million||$3.40 million||View||N/A|
|3/12/2015||Q4 2014||($0.32)||($0.27)||$6.12 million||$4.40 million||View||N/A|
|11/6/2014||Q314||($0.40)||($0.39)||$3.71 million||$4.40 million||View||N/A|
|8/14/2014||Q214||($0.13)||($0.11)||$3.72 million||$1.80 million||View||N/A|
Earnings Estimates for Arbutus Biopharma Corporation (NASDAQ:ABUS)
2017 EPS Consensus Estimate: ($1.53)
2018 EPS Consensus Estimate: ($1.53)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Arbutus Biopharma Corporation (NASDAQ:ABUS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Arbutus Biopharma Corporation (NASDAQ ABUS)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 66.93%
Insider Trades by Quarter for Arbutus Biopharma Corporation (NASDAQ ABUS)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/3/2017||Michael J Sofia||Insider||Sell||10,000||$8.00||$80,000.00|| |
|8/15/2017||Michael J Sofia||Insider||Sell||30,000||$3.70||$111,000.00|| |
|8/24/2015||Richard C Henriques Jr||Director||Buy||1,000||$6.95||$6,950.00|| |
Latest Headlines for Arbutus Biopharma Corporation (NASDAQ ABUS)
Arbutus Biopharma Corporation (NASDAQ ABUS) Chart for Sunday, November, 19, 2017